ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M. as chief financial officer (CFO) and head of business development. Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.
- WEST HILLS, Calif., Aug. 9, 2022 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M.
- as chief financial officer (CFO) and head of business development.
- Mr. Lamba replaces Anat Nursella, who served as CFO at ImmPACT Bio since late 2020.
- "It is exciting to join ImmPACT Bio at its current stage of successful product development and help scale-up and deliver the pipeline of next-generation CAR T-cell therapies," said Mr. Lamba.